Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KMO | O15229 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213138 | 0.88 | POLB (0.53) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL23213520 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL29944824 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL23239917 | 0.82 | POLB (0.75) | ALDH1A1MAPTHTTPOLBTSHR | |
| Hydrochloric Acid SCHEMBL25311845 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL29177336 | 0.81 | POLB (0.52) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL26741154 | 0.80 | POLB (0.60) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL7988768 | 0.79 | MEN1 (0.68) | ALDH1A1POLBTSHRNPC1KDM4E | |
| SCHEMBL26739658 | 0.78 | POLB (0.57) | ALDH1A1MAPTHTTPOLBTSHR | |
| SCHEMBL29177207 | 0.78 | POLB (0.54) | ALDH1A1MAPTHTTPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023001028-A1 | HETEROARYL-3-PIPERIDINEDIONE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-4041231-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | ALDH1A1 4150/4885MAPT 4671/4885HTT 868/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | ALDH1A1 1331/4885MAPT 4852/4885HTT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.